Condition: Castration-Resistant Prostate Carcinoma · Metastatic Prostate Adenocarcinoma · Stage IVB Prostate Cancer AJCC v8 · Sponsor: University of Michigan Rogel Cancer Center
This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production (castration-resistant) and that has spread from where it first started to other places in the body (metastatic). Ruxolitinib, a kinase inhibitor, slows down the growth of the tumor by blocking the proteins, JAK1 and JAK2, tumors use to grow. Enzalutamide, an androgen receptor inhibitor, works by blocking the effects of androgen (a male reproductive hormone). This may help stop the growth and spread of tumor cells that need testosterone to grow. Giving ruxolitinib in combination with enzalutamide may be safe, tolerable, and/or effective in treating metastatic castration-resistant prostate cancer.
This description comes directly from the study's public registry record.
Cancer AnswerLine · 1-800-865-1125 · CancerAnswerLine@med.umich.edu
Always discuss trial participation with your own doctor first.
| Rush University | Chicago, Illinois, United States | Not Yet Recruiting |
| University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06616155